Agnostic Metagenomic Next-Generation Sequencing (mNGS) for Clinical Diagnostics
Key Dates
Due Date
-
Posted Date
-
Agency & Value
Agency
W6QK ACC-APG
Contract Value
Not provided
Codes & Classification
Solicitation Number
W911SR-26-R-MNGS
NAICS
-
Classification Code
-
Additional Details
Documents1
The Department of Defense, through the Department of the Army and its contracting office W6QK ACC-APG, has issued a Sources Sought notice (Procurement Identifier: W911SR-26-R-MNGS) seeking industry input for the development of an agnostic metagenomic next-generation sequencing (mNGS) capability for clinical diagnostics. This initiative, led by the Capability Program Executive for Chemical, Biological, Radiological, and Nuclear Defense (CPE CBRND), is focused on advancing field-forward, threat-agnostic mNGS systems to rapidly identify a broad spectrum of infectious disease agents—including traditional, novel, emerging, and engineered pathogens—in operational military environments.
**Purpose and Scope**
The primary objective of this market research is to identify mature, portable, and integrated mNGS solutions that can overcome current technical and regulatory barriers, enabling deployment as routine clinical diagnostic tools, especially in resource-limited or austere settings. The envisioned capability is critical for military medical readiness and response, supporting Formation Based Layered Protection by facilitating early and accurate pathogen characterization. This will enhance the health, readiness, and resilience of the Armed Forces, allowing for timely and appropriate treatment decisions and sustaining combat power in the face of biological threats.
**Key Requirements and Expected Deliverables**
CPE CBRND is seeking collaboration with industry partners who can deliver innovative, end-to-end mNGS solutions addressing the following core challenges:
- **Integrated "Sample-to-Answer" System:** Fully automated, ruggedized platforms that minimize manual intervention from nucleic acid extraction through library preparation, sequencing, and bioinformatic analysis, ideally within a single workflow.
- **Host Nucleic Acid Depletion:** Efficient, unbiased methods for removing human DNA/RNA from clinical samples to enhance microbial detection.
- **Field-Forward Bioinformatics:** Computationally efficient, offline analysis pipelines with curated, regulatory-grade databases that are securely updateable, incorporating validated thresholds for confident pathogen identification.
- **Clinical Decision Support:** Advanced interpretive tools to distinguish true pathogens from contaminants or commensal organisms, generating actionable reports for non-specialist operators.
- **Host-Response Profiling (Stretch Goal):** Capabilities for transcriptomic analysis to identify gene expression signatures indicative of infection, providing diagnostic insight when direct pathogen detection is insufficient.
- **Regulatory Path:** Solutions must be supported by a viable regulatory strategy for FDA authorization (EUA, 510(k), or de novo), and a scalable manufacturing plan to meet military requirements. Experience with CLIA waiver criteria is also desirable.
The ideal product profile targets a portable, rapid, and easy-to-use mNGS system, preferably backpack-sized and battery-operable, with proven environmental robustness and real-time data analysis capabilities. The workflow should be fully automated, with minimal hands-on time (<15 minutes), and deliver actionable results within six hours. Long-read or ultra-long-read sequencing technology is highly desirable for de novo genome assembly. Offline, laptop-based bioinformatics pipelines with secure, updateable databases are required, along with automated quality filtering, host subtraction, and taxonomic classification.
**Submission Guidelines**
Respondents are requested to submit a five-page white paper and a one-page Quad Chart addressing technical approach and product maturity, bioinformatics and clinical interpretation, regulatory and clinical status, manufacturing and supply chain, company profile and vision, and information relevant to test and evaluation (T&E) partners. The government will prioritize responses demonstrating integrated, automated solutions with high-confidence results, particularly in the areas of technical maturity and bioinformatics.
T&E organizations are also invited to submit separate white papers detailing their experience in validating regulated medical devices, laboratory capabilities, regulatory and validation experience, and past performance in relevant diagnostic areas.
**Contracting Entity and Contact Information**
- **Contracting Entity:** W6QK ACC-APG (Federal Office)
- **Department:** Department of Defense
- **Agency:** Department of the Army
- **Place of Performance:** Frederick, Maryland, United States
- **Primary Contact:** Keith Pereira, Contract Specialist ([email protected])
- **General Inquiries:** [email protected]
**Procurement Type and Special Considerations**
This notice is a Sources Sought/Request for Information (RFI) and does not constitute a solicitation or a commitment to contract. Responses are for information and planning purposes only; unsolicited proposals or offers will not be considered. Respondents are responsible for all expenses associated with their submissions, which should not include proprietary or classified information.
**Constant Elements Over Contract Lifecycle**
The focus on mature, portable, and integrated mNGS systems for clinical diagnostics, the requirement for a robust regulatory path, and the emphasis on supporting military medical readiness and response will remain central throughout the contract lifecycle. The place of performance (Frederick, MD), the contracting entity (W6QK ACC-APG), and the contact points provided are fixed elements for this opportunity.
**Summary for Contractors**
This opportunity is well-suited for organizations with proven capabilities in developing and commercializing regulated molecular diagnostic devices, particularly those with expertise in next-generation sequencing, bioinformatics, and field-deployable medical technologies. Experience with FDA regulatory pathways and scalable manufacturing is essential. T&E organizations with relevant validation experience are also encouraged to respond. Interested parties should carefully review the detailed requirements and submit comprehensive responses by the specified deadline.
For further information and to access the official notice, visit: [SAM.gov Opportunity ID: e89e056ce8cf4f6cad5e4f9d6b593bf2](https://sam.gov/opp/e89e056ce8cf4f6cad5e4f9d6b593bf2/view).